benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

This publication has 27 references indexed in Scilit:

• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR * Trial)
  Published by Elsevier ,2003
• Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
  British Journal of Clinical Pharmacology, 2003
• Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
  American Heart Journal, 2002
• Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers
  British Journal of Clinical Pharmacology, 2002
• The effect of fluconazole on the pharmacokinetics of rosuvastatin
  European Journal of Clinical Pharmacology, 2002
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
  The American Journal of Cardiology, 2001
• Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
  European Heart Journal, 1998
• Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
  JAMA, 1993